drugset / Trial / NCT00002020

Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC

NCT00002020 ↗

Completed Glaxo Wellcome
Treatment

Summary

To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Zidovudine Small molecule — Oral